BRIEF—Peter Zerhouni steps down as CEO of InDex Pharma

Swedish immunology company InDex Pharmaceuticals today announced that after more than seven years as chief executive, Peter Zerhouni has decided to leave his position.

The company’s chief financial officer Johan Giléus has been appointed acting CEO while a new CEO is being recruited, and he will also continue as CFO.

“With the drug candidate cobitolimod in Phase III, a clear plan to market, and a solid financial position, InDex stands stronger than ever,” said Wenche Rolfsen, chairman of InDex Pharmaceuticals, adding: “I want to thank Peter for his contribution in building the company and for his good collaboration. I wish him all the best.”

The candidate is being developed for moderate to severe left-sided ulcerative colitis, with results from the Phase III CONCLUDE study expected in the latter half of 2023.

Cobitolimod has an annual sales potential of over a billion dollars in the target indication, with around 400,000 people suffering from the condition, despite the availability of therapeutic options, according to a previous statement by the company.

“It has been a rewarding journey and I am very proud of what the InDex team has accomplished during my time as CEO,” said Peter Zerhouni.

Peter Zerhouni will be available to the board during his notice period.